title: [Clinical features and prognosis of CD20-positive classical Hodgkin lymphoma].
abstract: OBJECTIVE
  To explore the clinical characteristics and prognosis of CD20-positive classical Hodgkin lymphoma (CHL).
  
  
  METHODS
  Data from CHL patients with CD20 immunohistochemical staining result who were treated in Cancer Hospital of Chinese Academy of Medical Sciences between September 2007 and March 2014 were reviewed. The relationship of CD20 expression in Reed-Sternberg(R-S)cells with CHL subtypes, clinical characteristics, and prognosis were analyzed. Fisher test was used to analyze the differences between groups and Kaplan-Meier for survival analysis.
  
  
  RESULTS
  A total of 263 patients were included in this study. Among the 263 patients, 74 (28.1%) were CD20-postitive. CD20-positive cases showed significantly higher proportions of Epstein-Barr virus (EBV) infection-related, mixed cellularity, and lymphocyte-rich CHL subtypes compared with CD20-negeative patients [52.8% (28/53) vs 19.0% (22/116), 37.9% (25/66) vs 31.6% (54/171), 22.7% (15/66) vs 3.5% (6/171), all P<0.05]. Univariate analysis identified EBV infection, age (≥ 40 years, especially ≥ 60 years), and Ⅲ-Ⅳ stage were correlated with reduced 3-year progression-free survival (PFS) and overall survival (OS) (PFS: 70.3 vs 87.7%, 79.2% vs 89.8%, 56.8% vs 91.5%, 70.4% vs 93.2%; OS: 81.0% vs 100%, 92.1% vs 99.4%, 75.4% vs 99.2%, 90.3% vs 100%; all P<0.05); and CD20-positive and not receiving local radiotherapy were associated with reduced PFS (79.7% vs 90.6%, 68.8% vs 90.6%, both P<0.05), not with OS (92.4% vs 98.3%, 94.0% vs 99.4%, both P>0.05). Patients positive in both CD20 expression and EBV-encoded small RNAs (EBER) showed low PFS.
  
  
  CONCLUSIONS
  CD20 expression in R-S cells in CHL may be closed related with EBV infection. EBV infection is associated with unfavorable prognosis. The effect of CD20-postitive on prognosis may be mediated by the prognostic effect of EBV infection.
authors.affiliation: Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Qin
authors.forename: S Y
authors.initials: SY
authors.lastname: Kang
authors.forename: X H
authors.initials: XH
authors.lastname: He
authors.forename: S Y
authors.initials: SY
authors.lastname: Zhou
authors.forename: P
authors.initials: P
authors.lastname: Liu
authors.forename: J L
authors.initials: JL
authors.lastname: Yang
authors.forename: C G
authors.initials: CG
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Yang
authors.forename: L
authors.initials: L
authors.lastname: Gui
authors.forename: Y K
authors.initials: YK
authors.lastname: Shi
mesh_terms: D018951:Antigens, CD20 / Q000378:metabolism*; D002452:Cell Count; D018572:Disease-Free Survival; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology / Q000821:virology; D006801:Humans; D011379:Prognosis; D016539:Reed-Sternberg Cells / Q000276:immunology* / Q000378:metabolism*
chemical_list: D018951:Antigens, CD20